Mizuho Markets Americas LLC Makes New $4.87 Million Investment in Kenvue Inc. (NYSE:KVUE)

Mizuho Markets Americas LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 226,375 shares of the company's stock, valued at approximately $4,874,000.

A number of other hedge funds also recently made changes to their positions in KVUE. Clearstead Advisors LLC bought a new position in shares of Kenvue during the 3rd quarter worth $25,000. Planned Solutions Inc. purchased a new position in shares of Kenvue in the fourth quarter worth about $27,000. Venturi Wealth Management LLC bought a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Kenvue during the 3rd quarter valued at approximately $28,000. Finally, Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue during the 4th quarter valued at approximately $28,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of analyst reports. HSBC boosted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a "hold" rating in a report on Wednesday, May 8th. William Blair assumed coverage on Kenvue in a report on Wednesday, April 3rd. They set a "market perform" rating for the company. The Goldman Sachs Group assumed coverage on shares of Kenvue in a report on Friday, March 1st. They issued a "neutral" rating and a $20.00 price target on the stock. Sanford C. Bernstein started coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an "underperform" rating and a $18.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an "outperform" rating on the stock in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and an average target price of $24.38.

Kenvue Trading Down 0.6 %

Shares of NYSE KVUE traded down $0.13 during trading hours on Friday, hitting $20.47. The company's stock had a trading volume of 31,071,005 shares, compared to its average volume of 25,622,140. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.43. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The business has a 50-day simple moving average of $20.04 and a 200-day simple moving average of $20.18. The stock has a market cap of $39.20 billion and a price-to-earnings ratio of 26.24.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.03. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The company's quarterly revenue was down 24.9% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date of this dividend is Tuesday, May 7th. Kenvue's payout ratio is 102.56%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.